Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P4, N=5000, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Aug 2026

Although the 9-valent HPV vaccine provides coverage for most circulating high-risk genotypes identified in the region, vaccination uptake remains inconsistent throughout Eastern Europe. The findings of this systematic review support the growing importance of extended HPV genotyping, molecular biomarkers, and microbiome-related approaches in cervical cancer prevention strategies in Eastern Europe. Strengthening organized screening programs, expanding vaccination coverage, and improving access to molecular diagnostic technologies remain essential priorities for reducing the regional burden of HPV-related disease.

P4, N=720, Recruiting, Xiamen Innovax Biotech Co., Ltd

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: May 2026 --> Jul 2026

P1, N=18, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Aug 2028 | Trial primary completion date: Jun 2026 --> Feb 2028

P4, N=400, Active, not recruiting, Zhejiang Provincial Center for Disease Control and Prevention | Recruiting --> Active, not recruiting

P3, N=6000, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2028 --> Nov 2029

Oral HPV genotyping in men with HIV reveals distinct oncogenic patterns, underscoring the need to monitor long-term OPSCC risk.

P4, N=30, Active, not recruiting, Medical College of Wisconsin | Trial primary completion date: Dec 2025 --> Dec 2028

P4, N=352, Active, not recruiting, Boston Medical Center | Trial completion date: Jun 2026 --> Oct 2026

P4, N=767, Completed, The University of Texas Medical Branch, Galveston | Active, not recruiting --> Completed

P=N/A, N=360, Not yet recruiting, Jiangsu Province Centers for Disease Control and Prevention